Engineered SIRPα variants as immunotherapeutic adjuvants to anticancer antibodies.
Engineered SIRPα variants as immunotherapeutic adjuvants to anticancer antibodies.
复制标题
DOI:
10.1126/science.1238856
复制
发表时间:
2013-07-05
期刊:
影响因子:
--
通讯作者:
Garcia KC
中科院分区:
文献类型:
--
作者:
Weiskopf K;Ring AM;Ho CC;Volkmer JP;Levin AM;Volkmer AK;Ozkan E;Fernhoff NB;van de Rijn M;Weissman IL;Garcia KC
During oncogenesis, tumors develop mechanisms to avoid rejection by the immune system. Recent studies have identified CD47 as an anti-phagocytic “don't eat me” signal tat cancer cells employ to inhibit macrophage-mediated destruction. Here, we modified the 14 kDa binding domain of human SIRPα, the receptor for CD47, for use as a CD47 antagonist. Using in vitro evolution via yeast surface display, we engineered high-affinity SIRPα variants with up to a 50,000-fold increase in affinity for human CD47 relative to wild-type SIRPα. As high-affinity SIRPα monomers, the variants potently antagonized CD47 on cancer cells, but to our surprise, they did not induce macrophage phagocytosis on their own. Instead, the high-affinity SIRPα monomers exhibited remarkable synergy with all tumor-specific monoclonal antibodies tested by increasing phagocytosis in vitro and enhancing anti-tumor responses in vivo. This novel “one-two punch” directs immune responses against tumor cells while lowering the threshold for macrophage activation, thereby providing a universal method for augmenting the efficacy of therapeutic anti-cancer antibodies.
登录
查看更多内容
影响因子:
64.5
作者:
Majeti R;Chao MP;Alizadeh AA;Pang WW;Jaiswal S;Gibbs KD Jr;van Rooijen N;Weissman IL
通讯作者:
Weissman IL
影响因子:
4.8
作者:
Hatherley, Deborah;Harlos, Karl;Barclay, A. Neil
通讯作者:
Barclay, A. Neil
影响因子:
11.5
作者:
Lapalombella, Rosa;Zhao, Xiaobin;Byrd, John C.
通讯作者:
Byrd, John C.
影响因子:
30.5
作者:
Takenaka, Katsuto;Prasolava, Tatiana K.;Danska, Jayne S.
通讯作者:
Danska, Jayne S.
影响因子:
56.9
作者:
Leach, DR;Krummel, MF;Allison, JP
通讯作者:
Allison, JP